Menu Search
Equities

Valeo Pharma Inc

VP2:BER

Valeo Pharma Inc

Actions
  • Price (EUR)0.064
  • Today's Change0.002 / 2.40%
  • Shares traded-1.00
  • 1 Year change-78.23%
  • Beta--
Data delayed at least 15 minutes, as of May 24 2024 14:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.

  • Revenue in CAD (TTM)54.29m
  • Net income in CAD-28.43m
  • Incorporated2003
  • Employees100.00
  • Location
    Valeo Pharma Inc16667 Hymus BlvdKIRKLAND H9H 4R9CanadaCAN
  • Phone+1 (514) 693-8832
  • Fax+1 (514) 693-8832
  • Websitehttps://valeopharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.